Neurological Biomarkers Market 2022 Key Players, SWOT Analysis, Key Indicators and Forecast to 2028

Global Neurological Biomarkers Market: Snapshot

The neurological biomarkers are specific to the detection or analysis of molecular mechanism taking place in a person’s neurological disorder. Though the market’s scope is restricted to just the neurological segment of a human body, it holds a huge market share in the coming years. The growth is primarily driven by the increase of neurological disorders. There is a huge increase in the rate of population suffering from disorders like Alzheimer, Parkinson, Schizophrenia, Depression and Multiple Sclerosis.  The prevalence of such diseases has also triggered the drug development practices. Many researches are solely dedicated to development of various drugs in the market which are based on the results of biomarkers. Thus, the global neurological biomarkers market is expected to proliferate in the coming years. The market includes highest application of neurological biomarkers for Alzheimer, which is expected to hold the highest market share of over US$ 2,100 Mn in the global neurological biomarkers market. However, new application areas like Schizophrenia and Spinal Muscular Atrophy are expected to witness more attractiveness in the global market, as both the segments are expected to lead with a growth at high rate.

The report also reveals the growth to be seen majorly in Asia Pacific during the forecast period. The region is expected to gain attractiveness in the coming years, as the neurological biomarkers market finds larger area of application and grow at a CAGR of 6.1% during the forecast period.

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-6626

Global Neurological Biomarkers Market: Upcoming Opportunities and Trends

Increasing prevalence of neurodegenerative disorders is expected to bolster the demand of neurological biomarkers in the global market. The growth is expected to introduce new trends in the market and help businesses capitalize on the opportunities coming their way. One of such trends is ELISA, which is a high sensitive method for detecting proteins in complex matrices such as urine, serum, plasma and saliva. It is considered as the best available method for quantification of proteins, and is also expected to gain traction in the coming years.  The major players that are behind introduction of such trends in the market and are also ruling the global neurological biomarkers market are Quanterix Corporation, Qiagen N.V., Thermo Fisher Scientific Inc. ADx Neurosciences NV, Merck KGaA., Acobiom, Banyan Biomarkers, Olink AB INC., Bio-Rad Laboratories, EuroImmun AG (Sub. PerkinElmer) etc.  There are many more trends in the market like mass spectroscopy and integrative biology. The coming years will project clear picture of the trend that will stand out and lead as a significant driver of global neurological biomarkers market.

What is the impact of COVID-19 on this industry?

According to an article “Biomarkers of COVID-19 and technologies to combat SARS-CoV-2” published in the U.S. National Library of Medicine, in August 2020, researchers are investigating the role of emerging biomarkers in the early detection of SARS-CoV-2. The results of this investigation may help the biomarkers market to develop in the post-pandemic era. Like other industries across the world, the neurological biomarkers industry was also negatively impacted during the peak of the COVID-19 pandemic. The disruption in manufacturing processes and supply-chain operations led to a stagnation of this industry. All the key players of the industry shifted their focus on the efforts to balance their overall losses due to the worldwide lockdown during the year 2020 which led to less focus on the research and development activities of their field. Furthermore, the implementation of biomarkers for early detection of COVID-19 has resulted in many companies focusing on the research and development of biomarkers, which will positively impact the market in the post pandemic era.